¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mixed lymphocyte reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • hemoclastic reaction
    Ç÷±¸ÆÄ±«¹ÝÀÀ
  • hemolytic transfusion reaction
    ¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • Herxheimer¡¯s reaction
    Ç츣ũ½ºÇÏÀ̸ӹÝÀÀ
  • heterogeneous reaction
    ÀÌÁú¹ÝÀÀ
  • heterophil antibody reaction
    ÀÌÁ¾Ä£È­Ç×ü¹ÝÀÀ
  • homograft reaction
    µ¿Á¾À̽ĹÝÀÀ
  • hopping reaction
    µµ¾à¹ÝÀÀ, ¾Ó°¨Áú¹ÝÀÀ
  • humoral reaction
    ü¾×¹ÝÀÀ
  • involutional depressive reaction
    °»³â±â¿ì¿ï¹ÝÀÀ
  • involutional paranoid reaction
    °»³â±âÆíÁý¹ÝÀÀ
  • involutional psychotic reaction
    °»³â±âÁ¤½Åº´¹ÝÀÀ
  • irreversible reaction
    ºñ°¡¿ª¹ÝÀÀ
  • isotherm reaction
    µî¿­¹ÝÀÀ
  • immune adherence reaction
    ¸é¿ªºÎÂø¹ÝÀÀ
  • immune reaction
    ¸é¿ª¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • febrile transfusion reaction
    ¹ß¿­¼öÇ÷ºÎÀÛ¿ë
  • Fernandez reaction
    (¢¡lepromin test) ·¹ÇÁ·Î¹Î°Ë»ç
  • Feulgen¡¯s reaction
    Æ÷ÀϰչÝÀÀ
  • fight-or-flight reaction
    (¢¡alarm reaction) ¾Ë¸²¹ÝÀÀ
  • first set reaction
    ÀÏÂ÷°ÅºÎ¹ÝÀÀ
  • flight reaction
    µµÇǹÝÀÀ
  • flocculation reaction
    ¼ØÅÐħÀü¹ÝÀÀ
  • foot placement reaction
    ¹ß³õ±â¹ÝÀÀ
  • footpad reaction
    ¹ß¹Ù´Ú¹ÝÀÀ
  • fuchsin number reaction
    Ç«½Å¼ö¹ÝÀÀ
  • fuchsinophil reaction
    Ç«½Åģȭ¹ÝÀÀ
  • reaction fever
    ¹ÝÀÀ¿­
  • reaction formation
    ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º
  • gel diffusion precipitin reaction
    ¿ì¹«È®»êħÀü¹ÝÀÀ
  • gluteal reaction
    º¼±â¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • primitive reaction
    ¿ø½Ã¹ÝÀÀ(¡­Úãëë).
  • principal reaction
    ÁÖ¹ÝÀÀ(ñ«Úãëë).
  • prolonged depressive reaction
    Áö¼ÓÀû¡¡¿ì¿ï¹ÝÀÀ
  • protracted reaction
    Áö¿¬¹ÝÀÀ(òÀæÅÚãëë).
  • prussian blue reaction
    °¨Ã»¹ÝÀÀ
  • psychogenic reaction
    ½ÉÀμº ¹ÝÀÀ(¡­Úãëë).
  • psychotic depressive reaction
    Á¤½ÅÁõÀû ¿ì¿ï¹ÝÀÀ(éØê¦Úãëë).
  • pyrogenic reaction
    ¹ß¿­¹ÝÀÀ.
  • pyrogenic reaction
    ¹ß¿­¹ÝÀÀ(Û¡æðÚãëë)
  • pyrrole reaction
    ÇǷѹÝÀÀ(¡­Úãëë).
  • quellung reaction
    ÆØÃ¢¹ÝÀÀ(ø³óìÚãëë).
  • rage reaction
    ³ë¹ÝÀÀ(ÖÍÚãëë).
  • rate limiting reaction
    ¼ÓµµÁ¦ÇѹÝÀÀ.
  • reaction accelerator
    ¹ÝÀÀÃËÁøÃ¼(Úãëë õµòäô÷).
  • reaction center
    Ȱ¼ºÁß½É(üÀàõñéãý).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • mixed salivary gland
    È¥ÇÕŸ¾×¼±, º¹ÇÕħ»ù
  • mixed sequence
    º¹ÇÕ ¿¬¼â
  • mixed small and large cell lymphoma
    È¥ÇÕ¼º ´ë¼Ò¼¼Æ÷ ¸²ÇÁÁ¾(¡­ ÓÞá³á¬øà ¡­ðþ)
  • mixed spicule
    È¥ÇÕħ°ñ(ûèùêöÜÍé).
  • mixed spicule
    È¥ÇÕ Ä§°ñ(ûèùêöÜÍé).
  • mixed suspended solid
    È¥ÇÕºÎÀ¯(°íÇü)¹°(¡­Ý©ë´Í³û¡Úª).
  • mixed thrombus
    È¥ÇÕÇ÷Àü(?Ì´Ëø).
  • mixed tocopherol concentrate
    ÅäÄÚÆä·Ñ³óÃàÇÕÁ¦(¡­ÒØõêùêð¥).
  • mixed tone
    º¹ÇÕÀ½
  • mixed tumor
    È¥ÇÕÁ¾¾ç(¡­ðþåË)
  • mixed tumor =pleomorphic adenoma
    È¥ÇÕÁ¾
  • mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
  • mixed vaccine
    È¥ÇÕ¹é½Å.
  • mixed venous blood
    È¥ÇÕÁ¤¸ÆÇ÷(ûèùêð¡Øæúì).
  • mixed-field agglutination
    È¥ÇսþßÀÀÁý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • third-order reaction
    »ïÂ÷ ¹ÝÀÀ (ß²ó­Úãëë)
  • time constant of a reaction
    ¹ÝÀÀ ½Ã°£»ó¼ö (ÚãëëãÁÊàßÈâ¦)
  • trigger reaction
    ¹æ¾Æ¼è ¹ÝÀÀ(Úãëë)
  • unimolecular reaction
    ÀϺÐÀÚ(ìéÝÂí­) ¹ÝÀÀ (Úãëë)
  • uphill reaction
    ¿À¸£¸· ¹ÝÀÀ (Úãëë)
  • van den Bergh reaction
    ¹Ý µ§ º£¸£±× ¹ÝÀÀ (Úãëë)
  • vectorial reaction
    ÁöÇâ(ò¦ú¾) ¹ÝÀÀ (Úãëë)
  • xanthoproteic reaction
    Ȳ´Ü¹éÁú(üÜÓ±ÛÜòõ) ¹ÝÀÀ(Úãëë)
  • yellow protein reaction
    Ȳ»ö ´Ü¹éÁú(üÜßäÓ±ÛÜòõ) ¹ÝÀÀ (Úãëë)
  • zero-order reaction
    ¿µÂ÷(çÍó­) ¹ÝÀÀ(Úãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
MFO medium frequency oscillator; mixed function oxidase
MGD maximal glucose disposal; mixed gonadal dysgenesis
MHA major histocompatibility antigen; May-Hegglin anomaly; Mental Health Association; methemalbumin; mic...
MHT mixed hemagglutination test
MIF macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
CTL-P Cytolytic T lymphocyte precursors
CTLA-4 Cytotoxic T Lymphocyte Antigen-4
CTLA-4 Cytotoxic T lymphocyte associated antigen 4
CTLp Cytotoxic T lymphocyte precursor
DLI Donor lymphocyte infusion
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • toxin antitoxin reaction
    µ¶¼Ò-Ç×µ¶¼Ò ¹ÝÀÀ
  • trimolecular reaction
    »ï ºÐÀÚ ¹ÝÀÀ
  • tuberculin reaction
    tuberculin ¹ÝÀÀ, Åõº£¸£Ä𸰠¹ÝÀÀ
  • two-phase color reaction
    µÎ °¡Áö »ö±ò ¹ÝÀÀ
  • uniphasic reaction
    ´Ü»ó ¹ÝÀÀ
  • untoward reaction
    ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Â ¹ÝÀÀ
  • vaccinoid reaction
    °¡µÎ¼º ¹ÝÀÀ
  • vascular reaction
    Ç÷°ü ¹ÝÀÀ
  • waking reaction
    °¢¼º ¹ÝÀÀ
  • wheal reaction
    µÎµå·¯±â ¹ÝÀÀ, ÆØÁø ¹ÝÀÀ
  • xanthydrol reaction
    À鯼µå·Ñ ¹ÝÀÀ
  • zona reaction
    Åõ¸í´ë ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
redox reaction <chemistry> A reaction in which one or more electrons are transferred.
(09 Jan 1998)
catalatic reaction Decomposition of H2O2 to O2 and H2O, as in the action of catalase; analogous to peroxidase reaction.
(05 Mar 2000)
catastrophic reaction The disorganised behaviour that is the response to a severe shock or threatening situation with which the person cannot cope.
(05 Mar 2000)
Mazzotti reaction A test for onchocerciasis using an oral test dose of diethylcarbamazine (50 or 100 mg), resulting in the appearance of an acute rash in 2 to 24 hours from death of microfilariae in the skin.
Synonym: Mazzotti reaction.
(05 Mar 2000)
Paul's reaction Pus is rubbed into a scarification on a rabbit's eye; if the pus is from a variolous or vaccinal pustule a condition of epitheliosis develops in from 36 to 48 hours; the sputum of a smallpox patient is said to cause the same reaction.
Synonym: Paul's test.
(05 Mar 2000)
cell-mediated reaction Immunological reaction of the delayed type, involving chiefly T lymphocytes, important in host defense against infection, in autoimmune diseases, and in transplant rejection.
See: skin test.
(05 Mar 2000)
Voges-Proskauer reaction A chemical reaction used in testing for the production of acetyl methyl carbinol by various bacteria; potassium hydroxide is added to a 24-hour culture in a suitable medium and thoroughly mixed; the treated culture is exposed to air and is observed at intervals of 2, 12, and 24 hours; a positive reaction consists of the development of an eosin-like pink colour, due to the production of acetylmethylcarbinol, which in the presence of alkali and oxygen is oxidised to diacetyl.
(05 Mar 2000)
chain reaction A reaction in which a product reacts and thus continues the reaction.
(09 Oct 1997)
Chantemesse reaction A conjunctival reaction, especially as applied to typhoid.
(05 Mar 2000)
reversed Prausnitz-Kustner reaction The appearance of an urticarial reaction at the site of injection when serum containing reaginic antibody is injected into the skin of a person in whom the allergen is already present.
(05 Mar 2000)
performic acid reaction Oxidative destruction of the ethylene double bond (-HC==CH-) which is converted to a Schiff-reactive double aldehyde; used to indicate the presence of unsaturated lipids, such as phospholipids and cerebrosides, as well as cystine-rich substances, such as keratin, in tissue sections.
(05 Mar 2000)
reversible reaction A chemical reaction that takes place in either direction i.e., from the forward or reverse direction; ionization is such a reaction, as are reaction's involving racemases, isomerases, mutases, transferases, etc.
(05 Mar 2000)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
chemical reaction <chemistry> A process in which one or more substances are changed chemically into one or more different substances.
(09 Oct 1997)
periodic acid Schiff reaction <technique> A histochemical technique based on periodic acid oxidation of a substance containing the 1,2-glycol grouping.
It is used for staining carbohydrates as the resulting dialdehyde reacts with Schiff reagent to form a coloured product.
The adjacent hydroxyl groups are oxidized to form aldehydes by periodic acid (HIO4) and these aldehyde groups react with Schiff's reagent (basic fuchsin decolourised by sulphurous acid) to give a purple colour.
Acronym: PAS
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á